MIAMI, Oct. 5, 2015— Global Stem Cells Group has announced that Augusto Brazzini, M.D., president of the Peruvian Society for Cellular Therapy, will appear as a featured lecturer at the Global Stem Cells Group Buenos Aires Symposium on Oct. 15, 2015.
Brazzini, a renowned physician and stem cell scientist, also founded the Brazzini Institute of Interventional Radiology in San Isidro, Peru. Brazzini will speak on the latest advancements in clinical applications for hematopoietic stem cells to treat Parkinson’s Disease and other chronic conditions.
He is also a professor at San Martin University in Lima, and vice president of the Peruvian Association of Cell Therapy (APTCEL,) a scientific and educational association created in Peru to promote the study, research and application of adult stem cell therapy.
Dr. Brazzini received his medical degree from Federicoima, Villarreal National University in 1977 and received additional training in radiology from San Marcos National University Police Peruvian Hospital and National Institute of Neoplasic Diseases.
For more information on the Global Stem Cells Group Buenos Aires symposium including the lineup of speakers, visit the stemcellconference.org website, firstname.lastname@example.org, or call +1 305 560 5337.
About the Global Stem Cell Group:
Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.
Global Stem Cells Group’s corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCG’s six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.